The global exosome diagnostic and therapeutic market was valued at $224.3 million in 2020, and is projected to reach $2,928.8 million by 2030, registering a CAGR of 29.4% from 2021 to 2030. Exosomes are small extracellular vesicles present in various body fluids, such as saliva, urine, blood, and breast milk. These vesicles play an important role in intercellular communication processes and have specific composition of proteins, lipids, messenger ribonucleic acid (mRNA), and micro ribonucleic acid (RNA). Presently, exosomes have great potential to be utilized for drug delivery and a biomarker for the diagnosis and testing of various diseases. Moreover, exosomes offer an alternative pathway for invasive biopsy used in the diagnosis and management of different types of cancer. The global exosome diagnostic and therapeutic market is driven by increase in prevalence of cancer, growth in initiatives implemented by the government and non-government associations, rise in health awareness, technological advancements in exosomes isolation, surge in analytical procedures, and increase in innovative and advanced applications of exosomes. However, stringent government regulations for the approval of exosomes diagnostic and therapeutic products and lack of awareness about the applications of exosomes restrict the market growth.
Furthermore, the developing countries, such as China and India are expected to provide huge growth opportunities to this market. The exosomes diagnostic and therapeutic market is segmented on the basis of application, product, end user, and region. As per the application, it is bifurcated into diagnostic and therapeutic applications. By the product, it is classified into instrument, reagents, and software. Depending on end user, it is segmented into cancer institute, hospitals, diagnostic centers, and others (medical universities and not-for-profit organizations). Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America dominated the market in 2020, and is expected to maintain its dominance throughout the forecast period, due to factors, such as increase in R&D investments, technological advancement in the exosomes isolation procedures, and rise in incidence of cancer. In addition, Asia-Pacific is expected to emerge as the area with maximum growth potential due to the increase in focus of key players on developing countries, rise in clinical research & trial outsourcing, growth in awareness & focus on health of the people, and surge in incidence of cancer & other chronic diseases.
The report provides a comprehensive analysis of the key players operating in the exosome diagnostics and therapeutic market, including Aethlon Medical, Inc. (U.S.), Exosome Diagnostics Inc. (U.S.), NanoSomix Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Malvern Instruments Ltd. (UK), System Biosciences Inc. (U.S.), NX Pharmagen (U.S.), Sistemic Inc. (UK), Capricor Therapeutics (U.S.), and Exiqon A/S (Denmark).
Furthermore, the developing countries, such as China and India are expected to provide huge growth opportunities to this market. The exosomes diagnostic and therapeutic market is segmented on the basis of application, product, end user, and region. As per the application, it is bifurcated into diagnostic and therapeutic applications. By the product, it is classified into instrument, reagents, and software. Depending on end user, it is segmented into cancer institute, hospitals, diagnostic centers, and others (medical universities and not-for-profit organizations). Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America dominated the market in 2020, and is expected to maintain its dominance throughout the forecast period, due to factors, such as increase in R&D investments, technological advancement in the exosomes isolation procedures, and rise in incidence of cancer. In addition, Asia-Pacific is expected to emerge as the area with maximum growth potential due to the increase in focus of key players on developing countries, rise in clinical research & trial outsourcing, growth in awareness & focus on health of the people, and surge in incidence of cancer & other chronic diseases.
The report provides a comprehensive analysis of the key players operating in the exosome diagnostics and therapeutic market, including Aethlon Medical, Inc. (U.S.), Exosome Diagnostics Inc. (U.S.), NanoSomix Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Malvern Instruments Ltd. (UK), System Biosciences Inc. (U.S.), NX Pharmagen (U.S.), Sistemic Inc. (UK), Capricor Therapeutics (U.S.), and Exiqon A/S (Denmark).
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the exosome diagnostic and therapeutic market analysis from 2020 to 2030 to identify the prevailing exosome diagnostic and therapeutic market opportunity.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the exosome diagnostic and therapeutic market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global exosome diagnostic and therapeutic market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Application
- Diagnostic
- Therapeutic
By Product
- Instrument
- Reagent
- Software
By End User
- Cancer Institute
- Hospital
- Diagnostic Center
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Aethlon Medical, Inc.
- Exosome Diagnostic, Inc.
- NanoSomix, Inc
- Thermo Fisher Scientific, Inc.
- Malvern Instruments Ltd
- System Biosciences, Inc
- NX Pharmagen
- Sistemic Ltd
- Capricor Therapeutics, Inc.
- Exiqon A/S
Frequently Asked Questions about the Global Exosome Diagnostic and Therapeutic Market
What is the estimated value of the Global Exosome Diagnostic and Therapeutic Market?
What is the growth rate of the Global Exosome Diagnostic and Therapeutic Market?
What is the forecasted size of the Global Exosome Diagnostic and Therapeutic Market?
Who are the key companies in the Global Exosome Diagnostic and Therapeutic Market?
| Report Attribute | Details |
|---|---|
| No. of Pages | 110 |
| Published | April 2022 |
| Forecast Period | 2020 - 2030 |
| Estimated Market Value ( USD | $ 224.3 million |
| Forecasted Market Value ( USD | $ 2928.8 million |
| Compound Annual Growth Rate | 29.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION
CHAPTER 5: EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT
CHAPTER 6: EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER
CHAPTER 7: EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY REGION
CHAPTER 8: COMPANY LANDSCAPE
CHAPTER 9: COMPANY PROFILES
LIST OF TABLES
LIST OF FIGURES
Executive Summary
According to this report titled, 'Exosome Diagnostic and Therapeutic Market,' the exosome diagnostic and therapeutic market size was valued at $224.34 million in 2020, and is estimated to reach $2.9 billion by 2030, growing at a CAGR of 29.4% from 2021 to 2030. Exosome diagnostic and therapeutic products are the medical instruments, which imply in the exosome-based research activities, used primarily in the investigation of various diseases, such as cancer and cardiac diseases, and others. The adoption of exosome instruments is increased among the healthcare and research professionals. The healthcare and research professionals provide immediate direction for the accurate diagnosis of diseases. In addition, technological advancements in the exosome isolation instruments attract end users to adopt the instruments for the isolation of micro and nanovesicle from the various types of body fluids.Major factors that boost the global exosome diagnostic and therapeutic market growth include increase in incidence of cancer, chronic, and infectious disease; growth in investments in R&D activities in exosome diagnostic and therapeutic industry; and surge in initiatives implemented by the government and non-government associations for healthcare development. In addition, technological advancements for easy exosome isolation and advancement in applications of exosome support the growth of the exosome diagnostic and therapeutic industry. In addition, the developing countries, such as China and India are expected to provide huge growth opportunities to the market. However, stringent government regulations for the approval of exosome diagnostic and therapeutic products and ack of awareness about the applications of exosome in developing countries restrict the market growth. The exosome diagnostic and therapeutic market analysis is segmented on the basis of application, product, end user, and region. On the basis of application, it is divided into diagnostic application and therapeutic application. Increase in demand for exosome as a biomarker in the diagnosis of cancer, surge in prevalence of cancer with rise in geriatric population, and growth in sedentary lifestyle are the major factors that contribute toward the growth of the exosome diagnostic market, and exosome therapeutic market.
Depending on product, the reagent segment held the largest market share in 2020, owing to its frequent use in healthcare facilities for the isolation of exosome and research procedures. However, the reagents segment is expected to witness considerable growth during the forecast period, owing to increase in need for molecular diagnosis and surge in R&D activities for the purpose of diagnosis. As per the end user, the diagnostic segment held the largest share of 30.3%.
Region wise, North American accounted 28.6% of the share in the market from 2021 to 2030, and is expected to maintain this leading position throughout the forecast period. The growth in the exosome diagnostic and therapeutic market in the region is attributed to the technological advancement in the isolation of exosomes, innovative and advanced applications of exosome-based products, and geriatric population coupled with increasing incidence of diseases, such as cancer and cardiovascular diseases. However, Asia-Pacific is projected to be the fastest-growing region, registering a CAGR of 30.3% during the exosome diagnostic and therapeutic market forecast period. This is mainly due to increase in awareness of innovative and advanced applications of exosome-based diagnostic and therapeutic products. In addition, increase in research outsourcing from emerging markets, rise in improvement of healthcare infrastructures, and surge in expenditures in the developing markets, such as India and China to overcome the unmet medical needs in these countries boost the market growth.
COVID-19 positively impacted the exosome diagnostic and therapeutic market share, due to rise in number of infectious disease cases, surge in availability of healthcare services in developing countries, and increase in demand for exosome diagnostic & therapeutic technology. Driving factors of the exosome diagnostic and therapeutic market are improvement in precision and surge in advantages over traditional methods of diagnosis and therapeutics.
Key findings of the Study
- By product type, the reagent segment was the highest contributor to the market in 2020.
- By application, the diagnostic segment was the highest contributor to the market in 2020.
- By end user, the cancer institute segment was the highest contributor to the market in 2020.
- Region wise, North American region garnered the largest revenue share in 2020; however, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.
Companies Mentioned
- Aethlon Medical, Inc.
- Exosome Diagnostic, Inc.
- NanoSomix, Inc
- Thermo Fisher Scientific, Inc.
- Malvern Instruments Ltd
- System Biosciences, Inc
- NX Pharmagen
- Sistemic Ltd
- Capricor Therapeutics, Inc.
- Exiqon A/S
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
